BioMarin Pharmaceutical (BMRN)
Health Care · Rare disease biotechnology / genetic medicine
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene therapies with a proven $3.2 billion commercial franchise.
What BioMarin Pharmaceutical does
BioMarin Pharmaceutical is a leading rare disease biotechnology company focused on developing and commercializing medicines for people with genetically defined conditions. The company's portfolio includes eight commercial therapies spanning enzyme replacement therapies for mucopolysaccharidosis (MPS) disorders, treatments for achondroplasia, phenylketonuria (PKU), neuronal ceroid lipofuscinosis, and gene therapies for hemophilia A, generating $3.2 billion in total revenues in 2025. BioMarin employs a distinctive approach to drug discovery and development, using genetic science to develop category-defining medicines with meaningful patient impact.
Themes: ["Rare genetic diseases","Enzyme replacement therapies","Gene therapies","Achondroplasia / growth disorders","Lysosomal storage disorders","Metabolic disorders","Hemophilia A gene therapy"]
Fundamentals
- Price$59.97 as of 2026-07-09 close
- Market cap$11.6B as of 2026-07-10
- 1-year return+3.0% as of 2026-07-09 close
- P/E43.00 as of 2026-07-10
- Net margin+8.3% as of 2026-07-10
- Gross margin+80.2% as of 2026-07-10
- ROE+4.4% as of 2026-07-10
- Debt / equity0.23 as of 2026-07-10
- Revenue growth (YoY)+9.9% as of 2026-07-10
- Revenue CAGR (3y)+15.4% SEC XBRL
- Beta0.23 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.